The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown. Results of the phase 2 trial, published in the ...
Fasenra (benralizumab) is a prescription drug that’s used to treat conditions such as eosinophilic asthma. Fasenra is given as an injection under your skin. This drug should not be used in certain ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic ...
After multiple failed trials of Fasenra in chronic obstructive pulmonary disease, AstraZeneca will move on to advancing two other biologics—Tezspire and tozorakimab—in the indication. (AstraZeneca) ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...
AstraZeneca’s Fasenra is already late to the game in nasal polyps, and now the drug is being pushed back even further—if it can eventually get there. The FDA has rejected AstraZeneca’s bid to expand ...
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
Fasenra (benralizumab) is a brand-name injection that’s prescribed for severe eosinophilic asthma in certain adults and children. As with other drugs, Fasenra can cause side effects, such as a ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on ...
Hypereosinophilic syndrome (HES) is a rare disease and involves long-term high levels of eosinophils (a type of white blood cell) in the blood. These eosinophils can collect in different tissues or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results